Sargramostim (GM-CSF) treatment for Alzheimer's disease
Phase II trial of GM-CSF/sargramostim in Alzheimer's Disease
Sargramostim (GM-CSF), an FDA-approved immune-boosting drug, is being given to older adults with mild-to-moderate Alzheimer's disease to see if it helps thinking and memory.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10763352 on NIH RePORTER |
What this research studies
If you join, you would receive injections of sargramostim (a drug that stimulates certain immune cells) on a schedule and come in for regular visits. The team will monitor memory and thinking tests, blood and other biomarkers linked to Alzheimer's, and brain imaging to check for safety and changes. This Phase II effort builds on earlier lab and small human work suggesting the drug might reduce brain amyloid and improve cognition. Study staff will watch closely for side effects and amyloid-related imaging abnormalities that have occurred with other Alzheimer therapies.
Who could benefit from this research
Good fit: Ideal candidates are older adults (commonly 65 and up) diagnosed with mild-to-moderate Alzheimer's disease who can receive injectable therapy and attend regular clinic visits.
Not a fit: People with advanced Alzheimer's, different types of dementia, certain blood or immune disorders, or those who cannot safely get sargramostim injections may not benefit or be eligible.
Why it matters
Potential benefit: If successful, the treatment could improve cognition or slow decline in people with mild-to-moderate Alzheimer's using a drug already approved for other uses.
How similar studies have performed: Preclinical mouse studies and observations in treated leukemia patients showed cognitive benefits, and a prior small Phase I/II Alzheimer trial and safety work provided encouraging signals though large-scale confirmation is still needed.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Potter, Huntington — University of Colorado Denver
- Study coordinator: Potter, Huntington
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.